Bversity

1st Ever Virtual College for Biotech

Name : A. Cathy Jemimah
Contact: cathyjemimah@gmail.com
Mobile: 9944006399
Title: Protein Structural analysis

Answer the following questions below and upload them in the google form.

1. You are targeting the P1 and P40/P90 proteins of Mycoplasma pneumoniae for inhibiting its pathogenic activity and comparative analysis.

    a. Mention potential binding sites on P1 and P40/P90 that could be targeted for inhibition.

    b. Discuss the potential challenges and limitations of targeting P1 and P40/P90 proteins for Mycoplasma pneumoniae treatment.

    c. Discuss the significance of this research in developing novel therapeutic strategies for Mycoplasma pneumoniae infections.

a. Potential binding sites of proteins - P1 and P40/P90 that could be targeted for inhibition



Fig 1: This snapshot has the 2D view of the binding sites found when docked P1 protein of *M.pneumoniae* with Sialyllactose and viewed using Discovery studio visualizer. It shows that there exists potential binding sites in P1 protein for efficient binding of sialyllactose which is a monosaccharide. Vanderwalls force and hydrogen bond interaction is seen between amino acids like Arginine(Arg), Glycine (Gly), Valine (Val) and Asparagine (Asn).



Fig 2: Here is the snapshot of the 2D view of the binding sites which are seen in P40/P90 protein of *M.pneumoniae* when docked with Sialyllactose and viewed using the Discovery studio visualizer. Various binding sites are found which show hydrogen bond interaction between various amino acids like Arginine(Arg), Glycine (Gly), Valine (Val), Asparagine (Asn), Lysine(Lys), Alanine(Ala) and Threonine(Thr).

b. Potential challenges and limitations of targeting P1 and P40/P90 proteins for *Mycoplasma pneumoniae* treatment.

Besides many advantages for opting P1 and P40/P90 proteins as a target for inhibition in *Mycoplasma pneumoniae* treatment, there are certain challenges that are still prevailing. Some of them are:

1) Mutation: *Mycoplasma pneumoniae* has a high rate of mutation which makes this method less useful rather than the commonly used techniques. Because of mutation, there is a high chance of conversion of proteins with different antigenic variants, which leads to drug resistance eventually.
2) No complete protection: Here, we are targeting only the external receptors of P1 and P40/P90 proteins, they only provide immunity only to a certain level. So even after receptor inhibition, there is a chance for the infection caused by the microbe to prevail in humans.
3) Host response: Different humans respond to this type of treatment in a different way. So, this method is not a generalized way of treating Pneumonia.
4) Immune response: This type of treatment does not create a long-lasting immune response, which causes this type of treatment to take a step back for treating Pneumonia in people with low or compromised immunity.
5) Sequence diversity : There are various types of P1 strains seen in *M.pneumoniae*, which is another obstacle for creating a common drug.

So, I think that though this technique seems fine and working, its technical applications and its implication in humans have certain challenges . This has to overcome serious problems like sequence diversity by identifying a way to develop broad spectrum inhibitors as antibiotics.This can be done by targeting conserved regions within P1 and P40/P90 sequences to overcome this issue.Also time duration for drug reaction can be speeded up for efficient use, by incorporating alternate delivery methods.

c. Significance of this research in developing novel therapeutic strategies for Mycoplasma pneumoniae infections.

This research has huge potential for developing drugs that have to focus on certain areas to overcome the limitations. By analyzing the potential binding sites and their interactions of P1 and P40/P90 proteins the **development of vaccines** that prevent adhesion and infection altogether can be made.Also by opting for targeted treatment strategies with **high specificity**, the risk of decreasing beneficial gut bacteria and causing collateral damage is drastically reduced, which is usually the case in using broad spectrum antibiotics. Another significance of opting for novel therapeutic strategies is its **high-impact for the target**. The main two proteins, P1 and P40/P90 are known for bacterial adhesion, motility and virulence. So when we are using a monosaccharide ligand like Sialyllactose to inhibit them would prevent further spread accompanied with colonization.This also reduces the damage made to host cells, which ultimately leverages the treatment efficiency. Also, opting for these techniques reduces **antibiotic resistance** which is a notable limitation in traditional antibiotic treatments for *M.pneumoniae*. When we understand these mechanisms and their science behind, new ideas can be incorporated further to eliminate the limitations and enhance the treatment strategy. For instance, introducing certain peptide inhibitors, monoclonal antibodies or small molecules which can interfere with the function of these proteins leading to **novel therapeutic strategies**.

In conclusion, targeting P1 and P40/P90 proteins of *M. pneumoniae* for inhibiting its pathogenic activity and also by conducting comparative analysis not only helps in understanding the biology and pathogenesis of the bacteria but also holds promise in developing novel and more effective therapeutic strategies against M. pneumoniae infections.